Senior adult oncology clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 3, Issue 4, 2005, Pages 572-590

  Balducci, Lodovico ^a   Cohen, Harvey Jay ^b   Engstrom, Paul F ^c   Ettinger, David S ^d   Halter, Jeffrey ^f   Gordon, Leo I ^e   Kiel, Krystyna ^e   Kneier, Andrew ^g   Lim, Dean ^h   Petersdorf, Stephen H ⁱ   Rosenthal, Ronnie ^l   Silliman, Rebecca ^l   Vose, Julie M ^j   Walker, Michael J ^k   Zachariah, Babu ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h City of Hope Cancer Center   (United States)

ⁱ Fred Hutchinson Cancer Research Center   (United States)

^j NEBRASKA MEDICAL CENTER   (United States)

^k OHIO STATE UNIVERSITY   (United States)

^l NONE

more..

Author keywords

Carcinoma; Chemotherapy; Elderly; Geriatrics; NCCN clinical practice guidelines; Supportive care

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FLUOROPYRIMIDINE DERIVATIVE; GEMCITABINE; GYRASE INHIBITOR; HEMOGLOBIN; HEMOPOIETIC GROWTH FACTOR; IDARUBICIN; NAVELBINE; PACLITAXEL; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE SULFATE; ERYTHROPOIETIN;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESEARCH; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EXCRETION; GERIATRIC ASSESSMENT; GLIOBLASTOMA; HEALTH SURVEY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIFESPAN; LUNG CANCER; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; ONCOLOGY; OSTEOSARCOMA; PATIENT IDENTIFICATION; PATIENT SELECTION; POPULATION RESEARCH; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; REVIEW; UNITED STATES; UNSPECIFIED SIDE EFFECT; VULNERABLE POPULATION; ADULT; AGED; ARTICLE; DAILY LIFE ACTIVITY; FRAIL ELDERLY; LIFE EXPECTANCY; NEOPLASM; STANDARD;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; ERYTHROPOIETIN; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HUMANS; LIFE EXPECTANCY; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 27744597661     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2005.0032     Document Type: Review

References (89)

1. Lichtman SM, Skirvin JA. Pharmacology of antineoplastic agents in older cancer patients. Oncology (Huntingt) 2000;14:1743-1755.
2. Muss HB. Older age-Not a barrier to cancer treatment. N Engl J Med 2001;345:1128-1129.
3. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
4. Balducci L, Beghé C. Cancer and age in the USA. Crit Rev Oncol Hematol 2001;37:137-145.
5. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004;22:4626-4631.
6. Saltzstein SL, Behling CA. 5- and 10-year survival in cancer patients aged 90 and older: a study of 37,318 patients from SEER. J Surg Oncol 2002;81:113-116.
7. Extermann M. Management issues for elderly patients with breast cancer. Curr Treat Options 2004;5:161-169.
8. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-1097.
9. Christman K, Muss HB, Case LD, et al. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience. JAMA 1992;268:57-62.
10. Chen H, Cantor A, Meyer J, et al. Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer 2003;15:1107-1114.
11. Balducci L, Corcoran MB. Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am 2000;14:193-212.
12. Cova D, Beretta G, Balducci L. Cancer chemotherapy in the older patient. In: Balducci L, Lyman GH, Ershler WB, eds. Comprehensive Geriatric Oncology. London: Harwood Academic Publishers; 1998:429-442.
13. Naeim A, Reuben D. Geriatric syndromes and assessment in older cancer patients. Oncology 2001;15:1567-1577.
14. Balducci L, Stanta G. Cancer and frailty: a coming epidemic. Hematol Oncol Clin North Am 2000;14:235-250.
15. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001;285:2750-2756.
16. Walter LC, Lindquist K, Covinsky KE. Relationship between health status and use of screening mammography and Papanicolaou smears among women older than 70 years of age. Ann Intern Med 2004;140:681-688.
17. Rao AV, Seo PH, Cohen HJ. Geriatric assessment and comorbidity. Semin Oncol 2004;31:149-159.
18. Extermann M, Meyer J, McGinnis M, et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol 2004;49:69-75.
19. Repetto L, Comandini D, Mammoliti S. Life expectancy, comorbidity and quality of life: the treatment equation in the older cancer patients. Crit Rev Oncol Hematol 2001;37:147-152.
20. Ingram SS, Seo PH, Martell RE, et al. Comprehensive assessment of the elderly cancer patient: the feasibility of self-report methodology. J Clin Oncol 2002;20:770-775.
21. Callen LJ, Vranas P, Overcash J, et al. Patterns of care and survival in cancer patients with cognitive impairment (Abstr). ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004;22:8083.
22. Monfardini S, Ferrucci L, Fratino L, et al. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 1996;77:395-401.
23. Balducci L, Extermann M. Cancer and aging: an evolving panorama. Hematol Oncol Clin North Am 2000;14:1-16.
24. Lachs MS, Feinstein AR, Cooney LM Jr, et al. A simple procedure for general screening for functional disability in elderly patients. Ann Intern Med 1990;112:699-706.
25. Moore AA, Siu AL. Screening for common problems in ambulatory elderly: clinical confirmation of a screening instrument. Am J Med 1996;100:438-443.
26. Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001;49:1691-1699.
27. Fried L, Tangen C, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol Med Sci 2001;56A: M146-M156.
28. Hamerman D. Toward an understanding of frailty. Ann Intern Med 1999;130:945-950.
29. Trask PC, Paterson A, Riba M, et al. Assessment of psychological distress in prospective bone marrow transplant patients. Bone Marrow Transplant 2002;29:917-925.
30. Patrick-Miller LJ, Broccoli TL, Much JK, et al. Validation of the Distress Thermometer: a single item screen to detect clinically significant psychological distress in ambulatory oncology patients (Abstr). ASCO Annual Meeting Proceedings (post-meeting edition). J Clin Oncol 2004;22:6024.
31. Jacobsen PB, Donovan KA, Trask PC, et al. Screening for psychologic distress in ambulatory cancer patients. Cancer 2005;103:1494-1502.
32. Fleishman SB. Treatment of symptom clusters: pain, depression, and fatigue. J Natl Cancer Inst Monogr 2004;32:119-123.
33. Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 2003;114:180-187.
34. Wilson CJ, Cohen HJ, Pieper CF. Cross-linked fibrin degradation products (D-dimer), plasma cytokines, and cognitive decline in community-dwelling elderly patients. J Am Geriatr Soc 2003;51:1374-1381.
35. Extermann M, Aapro M. Assessment of the older cancer patient. Hematol Oncol Clin North Am 2000;14:63-78.
36. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit of chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425.
37. Zinzani PG, Storti S, Zaccaria A, et al. Elderly aggressive histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen: experience in 350 patients. Blood 1999;94:33-38.
38. Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP vs CNOP chemotherapy. J Clin Oncol 1995;13:2530-2539.
39. Gomez H, Mas L, Casanova L, et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte- macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998;16:2352-2358.
40. Bastion Y, Blay J-Y, Divine M, et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival. A Group d'Etude des Lymphomes de l'Adulte Study on 453 patients older than 69 years. J Clin Oncol 1997;15:2945-2953.
41. Bertini M, Freilone R, Vitolo U, et al. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen. Leuk Lymphoma 1996;22:483-493.
42. O'Reilly SE, Connors JM, Howdle S, et al. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy. J Clin Oncol 1993;11:2250-2257.
43. Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. J Am Geriatr Soc 1984;32:269-273.
44. Rowe JM, Andersen J, Mazza JJ, et al. Phase III randomized-placebo controlled study on granulocyte macrophage colony-stimulating factor (GM-CSF) in adult patients with acute myelogenous leukemia. A study of the Eastern Cooperative Oncology Group. Blood 1995;86:257-263.
45. Schiffer CA. Hematopoietic growth factors as adjuncts to the treatment of acute myelogenous leukemia. Blood 1996;88:3675-3685.
46. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995;332:1671-1677.
47. Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor for elderly patients with previously untreated acute myelogenous leukemia: a Southwest Oncology Group Study (9031). Blood 1998;91:3607-3615.
48. Lancet JE, Willman CL, Bennett JM. Acute myelogenous leukemia and aging: clinical interactions. Hematol Oncol Clin North Am 2000;16:251-268.
49. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-895.
50. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
51. Pierelli L, Perillo A, Greggi S, et al. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin in combination chemotherapy. J Clin Oncol 1999;17:1288-1296.
52. Ratain MJ, Schilsky RL, Choi KE, et al. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther 1989;45:226-233.
53. Silber JH, Fridman M, Di Paola RS, et al. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 1998;16:2392-2400.
54. Gelman RS, Taylor SG. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer. The elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984;2:1406-1414.
55. Ibrahim NK, Frye DK, Buzdar AU, et al. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med 1996;156:882-888.
56. Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst 1993;85:1580-1584.
57. Giovannozzi-Bannon S, Rademaker A, Lai G, et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials. An Illinois Cancer Center Study. J Clin Oncol 1994;12:2447-2452.
58. Wildiers H, Highley MS, de Bruijn EA, et al. Pharmacology of anticancer drugs in the elderly population. Clin Pharmakinet 2003;42:1213-1242.
59. Rao A, Cohen HJ. Symptom management in the elderly cancer patient: fatigue, pain, and depression. J Natl Cancer Inst Monogr 2004;32:150-157.
60. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34:4-12.
61. Berger AM, Farr L. The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. Oncol Nurs Forum 1999;26:1663-1671.
62. Respini D, Jacobsen PB, Thors C, et al. The prevalence and correlates of fatigue in older cancer patients. Crit Rev Oncol Hematol 2003;47:273-279.
63. Jacobsen PB, Donovan KA, Weitzner MA. Distinguishing fatigue and depression in patients with cancer. Semin Clin Neuropsychiatry 2003;8:229-240.
64. Jacobsen PB. Assessment of fatigue in cancer patients. J Natl Cancer Inst Monogr 2004;32:93-97.
65. Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 1983;52:1986-1992.
66. Kim YJ, Rubenstein EB, Rolston KV, et al. Colony-stimulating factors (CSFs) may reduce complications and death in solid tumor patients with fever and neutropenia (Abstr #2411). Proc ASCO 2000;19:612a.
67. Crivellari D. Results of adjuvant treatments in breast cancer patients over 70 years old: the IBCSG experience. International Breast Cancer Study Group. Tumori 2002;88:S81-S82.
68. Lyman GH, Kuderer N, Agboola O, et al. Evidence-based use of colony-stimulating factors in elderly cancer patients. Cancer Control 2003;10:487-499.
69. Balducci L, Repetto L. Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer 2004;100:6-11.
70. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002;94:173-181.
71. Rocha Lima CM, Herndon JE 2nd, Kosty M, et al. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 2002;94:181-187.
72. Neubauer M, Schwartz J, Caracandas J, et al. Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group Performance Status of 2, or age > or = 70 years. J Clin Oncol 2004;22:1872-1877.
73. Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997;89:3974-3979.
74. Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:3840-3848.
75. Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3041-3050.
76. Extermann M, Bonetti M, Sledge GW, et al. MAX2-a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer 2004;40:1193-1198.
77. Timmer Bonte J, Biesma B, Smit J, et al. Prevention of chemotherapy-induced febrile neutropenia (FN) by antibiotics (AB) versus antibiotics plus granulocyte-colony stimulating factor (G-CSF) in small cell lung cancer (SCLC): a randomized phase III study (Abstr). ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004;22:8002.
78. Repetto L, Biganzoli L, Koehne CH, et al. EORTC Cancer in the Elderly Task Force Guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 2003;39:2264-2272.
79. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-4107.
80. Metivier F, Marchais SJ, Guerin AP, et al. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant 2000;15:14-18.
81. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000;35:1737-1744.
82. Wu WC, Rathore SS, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001;345:1230-1236.
83. Pickett JL, Theberge DC, Brown WS, et al. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999;33:1122-1130.
84. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
85. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
86. Lipman AJ, Lawrence DP. The management of fatigue in cancer patients. Oncology (Huntingt) 2004;18:1527-1534.
87. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004;100:2026-2046.
88. Peterson DE, Petit RG. Phase III study: AES-14 in patients at risk for mucositis secondary to anthracycline-based chemotherapy (Abstr). ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004;22:8008.
89. Balducci L, Extermann M. Management of the frail patient with advanced cancer. Crit Rev Oncol Hematol 2000;33:143-148.